Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

@article{Li2006BindingOG,
  title={Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients},
  author={Juan Li and Julie Renee Brahmer and Wells A. Messersmith and M V Mart{\'i}nez Hidalgo and Sharyn D. Baker},
  journal={Investigational New Drugs},
  year={2006},
  volume={24},
  pages={291-297}
}
Gefitinib exhibits wide inter-subject pharmacokinetic variability which may contribute to differences in treatment outcome. Unbound drug concentrations are believed to be more relevant to pharmacological and toxicological responses than total drug. Thus it is desirable to determine gefitinib binding in plasma and factors affecting this process. An equilibrium dialysis method using 96-well microdialysis plates was optimized and validated for determining the fraction unbound (fu) gefitinib in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients (Abstract)

  • J Li, MO Karlsson, J Brahmer, G Cusatis, M Hidalgo, SD Baker
  • Proc Amer Soc Clin Oncol 23:3083,
  • 2005
2 Excerpts

Similar Papers

Loading similar papers…